Hims & Hers Health, Inc.
HIMS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 1.21 | 0.45 | -0.83 |
| FCF Yield | 3.80% | 2.52% | -2.58% | -3.22% |
| EV / EBITDA | 63.45 | -89.10 | -20.74 | -10.43 |
| Quality | ||||
| ROIC | 22.21% | -9.08% | -21.45% | -32.62% |
| Gross Margin | 79.45% | 81.99% | 77.57% | 75.22% |
| Cash Conversion Ratio | 1.99 | -3.12 | 0.40 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.98% | 47.47% | 52.44% | 48.78% |
| Free Cash Flow Growth | 322.07% | 239.12% | 14.31% | -487.29% |
| Safety | ||||
| Net Debt / EBITDA | -2.65 | 4.35 | 0.68 | 0.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.71 | 6.99 | 5.48 | 4.97 |
| Cash Conversion Cycle | -30.68 | -45.07 | -31.12 | -28.14 |